Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KRAKEN: Phase 2 Study of Oral LY3473329 in Adults With Elevated Lipoprotein(a)
jRCT2031220462Phase 2Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2022
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of muvalaplin in lipoprotein(a) hyperlipoproteinemia (Lp(a)), atherosclerotic disease, coronary arteriosclerosis and 4 more (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Percent Change from Baseline in Lipoprotein(a) [Lp(a)]. Started Nov 2022; status: active, not recruiting.
02
Drugs
muvalaplin
03
Conditions
lipoprotein(a) hyperlipoproteinemia (Lp(a))atherosclerotic diseasecoronary arteriosclerosisischemic strokearteriosclerosis obliterans
Beyond the preview
Go deeper on jRCT2031220462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220462.